High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Inclusion Criteria

• •Diagnosis of multiple myeloma or plasma cell leukemia with documented relapsed or refractory disease according to International Myeloma Working Group (IMWG) criteria, in any one of the following categories:
• •* 3 prior lines of therapy including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI)
• •* Less than a very good partial response (VGPR) to initial therapy
• •* Early relapse (\< 12 months) after autologous hematopoietic cell transplant (HCT) or after 1st line of therapy
• •Collection of a bone marrow, fluid or tissue sample that is expected to have enough cells to run the assay
• •Measurable disease defined by one of the following:
• •* Serum monoclonal protein \>= 0.5 g/dL by serum protein electrophoresis (SPEP)
• •* \>= 200 mg/monoclonal protein in urine on 24 hr urine protein electrophoresis (UPEP)
• •* Involved serum free light chain (FLC) \>= 10 mg/dL and abnormal involved:uninvolved ratio
• •* Plasma cytomas that are palpable per exam or measurable per standard radiologic review
• •* Circulating plasma cells \>= 2,000 if diagnosis of plasma cell leukemia
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
• •Female patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth control
• •Ability to understand purpose and risks of the study and provide signed and dated informed consent, and authorization to use protected health information
• •Expected survival is \> 100 days
• •Adequate organ function as determined by the investigator